Compare C3.ai Inc (AI) vs Amylx Pharmaceuticals Inc (AMLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
C3.ai Inc vs Amylx Pharmaceuticals Inc — how do they compare? C3.ai Inc trades at $10.14 (market cap $1.65B), while Amylx Pharmaceuticals Inc trades at $23.87 (market cap $2.64B). The key difference: Amylx Pharmaceuticals Inc is the larger of the two by market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, C3.ai Inc nearer its low. Which is the better fit depends on your goals.
| AI | AMLX | |
|---|---|---|
Market Cap | $1.65B | $2.64B |
Sector | Technology | Health |
52-Week High | $19.66 | $24.19 |
52-Week Low | $7.76 | $7.82 |
Enterprise Value | $1.08B | $2.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
C3.ai (AI) trades at $10.40, up 1.76% with a bullish technical signal despite negative profitability metrics. The company reported Q1 2026 earnings beat but maintains negative net margins of -187.95%. Recent news highlights C3.ai being named a leader in AI platforms by Forrester Research, while technical indicators show RSI levels near 90 suggesting overbought conditions.
The stock faces significant fundamental challenges with persistent losses and negative cash flow, though revenue growth and leadership positioning in enterprise AI provide long-term potential. Analyst consensus is mixed with a $10.20 price target, indicating cautious optimism amid execution risks and competitive pressures in the AI software market.
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About C3.ai Inc
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Read more on AI →About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →
